Baxter International Inc. (NYSE:BAX) is a prominent player in the medical products industry, providing essential healthcare solutions worldwide. The company specializes in products for renal care, medication delivery, and surgical care. Despite its strong market presence, Baxter faces competition from other industry giants like Medtronic and Becton Dickinson.
On July 31, 2025, Goldman Sachs downgraded Baxter to a Neutral grade, following an earnings miss and a guidance cut. At the time, the stock was priced at $21.76. This downgrade came after Baxter reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.60. This earnings miss represented a negative surprise of 1.67%.
Baxter's revenue for the quarter ending June 2025 was $2.81 billion, which also fell short of the Zacks Consensus Estimate by 0.28%. This was a significant drop from the $3.81 billion reported in the same period the previous year. Despite this, Baxter has exceeded consensus revenue estimates twice in the last four quarters, showing some resilience.
The company's gross margin decreased by 170 basis points to 40.7%, mainly due to product mix pressures. However, the operating margin improved by 180 basis points to 15.1%. This indicates that while Baxter faced challenges in revenue and earnings, it managed to improve operational efficiency.
Baxter revised its full-year 2025 EPS guidance downward to a range of $2.42 to $2.52, from the previous range of $2.47 to $2.55. This revision is partly due to the impact of Hurricane Helene, which damaged a key manufacturing facility and reduced demand for IV solutions. The stock price reflects these challenges, with a 22.42% decrease, trading between $21.47 and $24.16 today.
